Press releases
BioCryst new long-term study data and an independent 6 month follow up of patients enrolled in the UK Early Access to Medicines Scheme (EAMS) demonstrates the long-term impact of prophylactic Orladeyo® (berotralstat) on HAE
By rpender
5 July 2022